Paratek Pharmaceuticals Stockholders Approve of Acquisition by Novo Holdings
Deal includes all company assets.
Paratek Pharmaceuticals has officially announced that based on a vote count, its stockholders have approved a merger agreement proposal at a special stockholders meeting, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). According to a company press release, final results of the voting will be disclosed on Form 8-K filed by Paratek with the U.S. Securities and Exchange Commission.
Paratek’s lead product, Nuzyra (omadacycline), is currently available in the US for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). In 2019, the company was presented with contract from the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA), currently valued at $304, aiming to development and US-based manufacturing of Nuzyra for pulmonary anthrax.
Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes.
Reference: Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S. Paratek Pharma. September 18, 2023. Accessed September 19, 2023. https://www.paratekpharma.com/investor-relations/press-release
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
